Although resistance develops in response to androgen receptor-targeted therapy in advanced prostate cancer, the underlying mechanisms remain unclear. The protein ZMYND8 is now shown to bind FOXM1 and the SWI–SNF complex, promoting the onset of neuroendocrine prostate cancer, which can thus be abrogated through small-molecule ZMYND8 inhibition.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Change institution
Buy or subscribe
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Learn more
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Learn more
Buy this article
Purchase on SpringerLink
Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Fig. 1: The AR inhibitor ENZ induces ZMYND8-dependent epigenetic alterations involving FOXM1 and the SWI–SNF complex, which drives the CRPC-to-NEPC transition and can be targeted by a small molecule.
References
Aggarwal, R. et al. J. Clin. Oncol. 36, 2492–2503 (2018).
ArticleCASPubMedPubMed CentralGoogle Scholar
Bluemn, E. G. et al. Cancer Cell 32, 474–489.e476 (2017).
ArticleCASPubMedPubMed CentralGoogle Scholar
Mu, P. et al. Science 355, 84–88 (2017).
ArticleCASPubMedPubMed CentralGoogle Scholar
Nouruzi, S. et al. Nat. Commun. 13, 2282 (2022).
ArticleCASPubMedPubMed CentralGoogle Scholar
Dardenne, E. et al. Cancer Cell 30, 563–577 (2016).
ArticleCASPubMedPubMed CentralGoogle Scholar
Bishop, J. L. et al. Cancer Discov. 7, 54–71 (2017).
ArticleCASPubMedGoogle Scholar
Wang, H. et al. Nat. Cancerhttps://doi.org/10.1038/s43018-025-00928-z (2025).
Kuroyanagi, J. et al. FEBS Lett. 588, 3409–3416 (2014).
ArticleCASPubMedGoogle Scholar
Li, N. et al. Mol. Cell 63, 470–484 (2016).
ArticleCASPubMedPubMed CentralGoogle Scholar
Mukherjee, S. et al. Cell Death Dis. 11, 1073 (2020).
ArticleCASPubMedPubMed CentralGoogle Scholar
Ghosh, K. et al. Cell Rep. 24, 2141–2154.e2146 (2018).
ArticleCASPubMedPubMed CentralGoogle Scholar
Chen, Y. et al. J. Clin. Invest. 128, 1937–1955 (2018).
ArticlePubMedPubMed CentralGoogle Scholar
Aggarwal, R. R. et al. Mol. Cancer Res. 17, 1235–1240 (2019).
ArticleCASPubMedPubMed CentralGoogle Scholar
Tang, F. et al. Science 376, eabe1505 (2022).
ArticleCASPubMedPubMed CentralGoogle Scholar
Xiao, L. et al. Nature 601, 434–439 (2022).
ArticleCASPubMedGoogle Scholar
Download references
Author information
Authors and Affiliations
Weill Cornell Graduate School of Medical Sciences, New York, NY, USA
Kate E. Dunmore
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
Kate E. Dunmore & David S. Rickman
Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA
David S. Rickman
Authors
Kate E. Dunmore
View author publications
You can also search for this author in PubMedGoogle Scholar
2. David S. Rickman
View author publications
You can also search for this author in PubMedGoogle Scholar
Corresponding author
Correspondence to David S. Rickman.
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
Reprints and permissions
About this article
Check for updates. Verify currency and authenticity via CrossMark
Cite this article
Dunmore, K.E., Rickman, D.S. Targeting anti-androgen therapy resistance through epigenetic rewiring. Nat Cancer (2025). https://doi.org/10.1038/s43018-025-00906-5
Download citation
Published:18 March 2025
DOI:https://doi.org/10.1038/s43018-025-00906-5
Share this article
Anyone you share the following link with will be able to read this content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative